GLSI Greenwich LifeSciences Inc.

FDA Catalyst Company
9.1
+0.44  (+5%)
Previous Close 8.66
Open 9.1
52 Week Low 8.19
52 Week High 48.96
Market Cap $117,858,222
Shares 12,951,453
Float 3,726,350
Enterprise Value $84,955,313
Volume 103,161
Av. Daily Volume 70,723
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 09/01/2021
Aegis Capital Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 01/27/2021
Aegis Capital Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 01/26/2021

Latest News

  1. Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced today it would resume its existing Stock Repurchase Program.

    Under the repurchase program previously authorized by the board of directors, Greenwich LifeSciences may repurchase its outstanding shares of common stock from time to time in open market or privately-negotiated transactions, including accelerated share repurchase transactions, block trades, or pursuant to 10b5-1 trading plans. Any repurchases will be at management's discretion and will be subject to market conditions, the price of the Company's shares and other factors. The stock repurchase program may be modified, suspended or…

    View Full Article
    • FDA review of manufacturing plans and pharmacy procedures associated with a recently placed clinical hold on the FLAMINGO-01 phase III clinical trial is underway with formal feedback from the FDA expected shortly. Greenwich is prepared to address FDA manufacturing and pharmacy procedure hold issues so that FLAMINGO-01 can commence as soon as possible.
    • Negotiations of clinical trial contracts and budgets for the first 3 large hospital sites and the largest oncology network in the US are completed and in the execution phase, paving the way for site initiation visits and subsequent site activation. Following site activation, patients will be screened, tested for HLA type, randomized and enrolled into any of 3 arms, and treated. Patients who…
    View Full Article
  2. Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that Snehal Patel, CEO of Greenwich LifeSciences, will participate in the following upcoming investor, partnering, and scientific conferences:

    H.C. Wainwright Global Investment Conference – May 23-26, 2022

    The Company will be participating in the H.C. Wainwright Global Investment Conference in Miami, Florida with an in-person presentation and will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference…

    View Full Article
  3. Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following:

    • Company management presented 2 Phase IIb clinical trial posters at the American Association for Cancer Research (AACR) Annual Meeting 2022, which was held from April 8-13, 2022 in New Orleans, Louisiana
    • Both abstracts can be viewed below, and both posters, CT166 and CT161, can be accessed or downloaded from the Clinical Trials tab of the Company website at: https://greenwichlifesciences.com/clinical-trials/
    • Abstract and poster CT166 demonstrated that GLSI-100 safely…
    View Full Article
    • The Phase III clinical trial, Flamingo-01, is now registered on clinicaltrials.gov with identifier NCT05232916 (view here), where more details about the trial design and a preliminary listing of the initial clinical sites can be found
    • Company management will be attending the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, which will be held from April 8-13, 2022 in New Orleans, Louisiana
    • A GP2 Phase III clinical trial poster will be presented in-person to provide updates on the Phase III clinical trial, Flamingo-01, and to continue the recruitment of clinical sites
    • Two additional posters will be presented in-person that cover additional findings from the Phase IIb clinical trial that we expect will lead…
    View Full Article
View All Greenwich LifeSciences Inc. News